Skip to content

Interest Income at other companies

Incyte logo
IncyteINCY
$33.69M+46.9%
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$6.66M+276%
LQD
Liquidia CorporationLQDA
$1.77M+2.5%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
$8.74M+11.5%
Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM
$3.55M-2.3%
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
$4.61M+12.6%

Segments

By segment

See full
Reportable Segment$2.28M-10.3%

Other financials

Income statement

See full
Revenue$105.4M+60.1%
Gross profit$95.6M+67.7%
Operating income-$9.1M+62.9%
Net income-$11.3M+54.9%
EPS (diluted)-$0.09+55.0%

Balance sheet

See full
Cash & equivalents$35.1M-34.7%
Total debt$114.7M+3.5%
Total equity$189.6M+32.9%
Total assets$460.0M+33.7%

Cash flow

See full
Operating cash flow$2.2M+107%
CapEx--100%
Free cash flow$2.2M+107%

Valuation

See full
Market cap$3.29B+57.5%

Profitability

See full
Gross margin90.9%+2.5pp
Operating margin-12%-5.7pp
Net margin-13.9%-6.6pp
FCF margin-52.5%-21.9pp

Returns & leverage

See full
Return on equity-28.2%-13.0pp
Debt / equity0.6×-0.2×
Current ratio2.7×-0.9×

Where this comes from

Reported directly by Arcutis Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InterestIncomeOther.

The official record: Arcutis Biotherapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arcutis Biotherapeutics, Inc.'s interest income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arcutis Biotherapeutics, Inc.'s interest income?
Arcutis Biotherapeutics, Inc. (ARQT) reported interest income of $2.28M in Q1 2026.
How has Arcutis Biotherapeutics, Inc.'s interest income changed year-over-year?
Arcutis Biotherapeutics, Inc.'s interest income decreased by 10.3% year-over-year, from $2.54M to $2.28M.
What does interest income mean?
Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.